Key statistics
As of last trade Exelixis Inc (EXEL:NSQ) traded at 41.01, -17.35% below its 52-week high of 49.62, set on Jun 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 42.00 |
|---|---|
| High | 43.25 |
| Low | 39.71 |
| Bid | 41.01 |
| Offer | 41.07 |
| Previous close | 44.06 |
| Average volume | 2.83m |
|---|---|
| Shares outstanding | 259.71m |
| Free float | 253.45m |
| P/E (TTM) | 15.83 |
| Market cap | 11.44bn USD |
| EPS (TTM) | 2.78 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 18:44 GMT.
More ▼
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
